A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1980

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Eloralintide
DRUG: Placebo

Sponsor

Eli Lilly and Company